Editas Medicine schedules 2026 EDIT-401 dosing and appoints CMO
Editas Medicine said it plans a 2026 start for EDIT-401 dosing in HeFH, with initial safety readout expected in early 2027, and named Daniel Ory, M.D. as CMO while awarding inducement options for up to 950,000 shares.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.